Results 111 to 120 of about 17,588 (197)

Phase I and pharmacologic study of topotecan in patients with impaired renal function.

, 1996
PURPOSE To determine the toxicities, pharmacokinetics, and recommended doses of the topoisomerase I inhibitor, topotecan, in patients with varying degrees of renal excretory dysfunction.
A A Forastiere, S O'Reilly, T L Chen, L B Grochow, D S Ettinger, S Sartorius, E K Rowinsky, W Slichenmyer, R C Donehower   +8 more
core   +1 more source

Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects

, 2000
PURPOSE: In in vitro studies, synergism and sequence-dependent effects were reported for the combination of topotecan and cisplatin. Recently, an oral formulation of topotecan became available.
Walter J. Loos, Jaap Verweij, Eddie Doyle, Hans Gelderblom, André S. Th. Planting, Marijke A. Mantel, Graham Ross, Solange Hearn, Eric Brouwer, Vera van Beurden, Maja J. A. de Jonge, Maria E. L. van der Burg, Alex Sparreboom   +12 more
core   +1 more source

Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway

, 2018
Mohammad Hassan Hodroj, Achraf Jardaly, Sarah Abi Raad, Annalise Zouein, Sandra Rizk Department of Natural Sciences, Lebanese American University, Beirut, Lebanon Background: Topotecan (TP) is an anticancer drug acting as topoisomerase I inhibitor that ...
Abi Raad S, Rizk S, Jardaly A, Hodroj MH, Zouein A   +4 more
core  

Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan. [PDF]

Front Immunol
Wang J, Jiang H, Niu J, Liu L, Wu Y, Shi J, Liu L, Yin S, Feng C, Zhang L, Yang M, Yi Z.   +11 more
europepmc   +1 more source

A study of variable hydration states in topotecan hydrochloride

, 2006
Topotecan hydrochloride, a pharmaceutical compound developed as a treatment for cancer, exhibits variable hydration states in a crystalline solid form chosen for manufacturing. This variability requires additional controls for successful development, and
Frederick G Vogt, Charles W Debrosse, Ann M Diederich, Gary E Zuber, Philip C Dell'orco, Jeffery L Wood, Lee M Katrincic, David J Busby, Ronald L Mueller, Qiaogong Su   +9 more
core  

Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer. [PDF]

Exp Hematol Oncol
Chiappa M, Villa V, Sias F, Grasselli C, Sala L, Canesi S, Marabese M, Mason S, Dibitetto D, Fruscio R, Damia G.   +10 more
europepmc   +1 more source

Multi-Omics Identification of UBE2C as a Prognostic Biomarker and Therapeutic Target Linked to Topotecan Sensitivity in Cervical Cancer. [PDF]

Oncol Res
Raj EN, Li CJ, Cheng SH, Yong SB, Wen ZH, Chiang AJ.   +5 more
europepmc   +1 more source

Intra-arterial chemotherapy for retinoblastoma: a structured narrative review. [PDF]

World J Pediatr Surg
Ren YH, Kang D, Shi C, Sun W.
europepmc   +1 more source

Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma. [PDF]

Ophthalmol Sci
Raval V, Arawindh R, Naik S, Jakati S, Venuganti VVK.   +4 more
europepmc   +1 more source

Integrative single-cell eQTL and multi-omics analyses reveal AIM1 and ANXA1 as immune-related hub genes and potential therapeutic targets in head and neck cancer. [PDF]

Front Oncol
Xue Z, Shen G, Lin G, Xue H, Wang R, Zhou Y, Chen Y, Wang K, Dai Y.   +8 more
europepmc   +1 more source